Publications

• Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.
  ESMO Open Volume: 10 Page(s): 105308
  06/05/2025 Authors: Nanda R; Yam C; Spring L; Bhave MA; Ntalla I; Valdez T; Stwalley B; Liang C; Wu W-H; Sjekloca N
• Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.
  Clin Breast Cancer
  04/08/2025 Authors: Jhaveri K; Anders CK; Bardia A; Bhave M; Chien AJ; Krop I; Traina TA; Abdou Y; Basho R; Conlin AK
• Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
  J Clin Oncol Volume: 42 Page(s): 4173 - 4186
  12/10/2024 Authors: Jhaveri KL; Lim E; Jeselsohn R; Ma CX; Hamilton EP; Osborne C; Bhave M; Kaufman PA; Beck JT; Manso Sanchez L
• A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
  Clin Cancer Res Volume: 30 Page(s): 5304 - 5313
  12/02/2024 Authors: Neven P; Stahl N; Vidal M; Martn M; Kaufman PA; Harbeck N; Hunt KK; Carter S; Bidard F-C; Fasching PA
• Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
  Breast Cancer Res Treat Volume: 208 Page(s): 203 - 214
  11/01/2024 Authors: Kalinsky K; Spring L; Yam C; Bhave MA; Ntalla I; Lai C; Sjekloca N; Stwalley B; Stokes M; Taylor A
• Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
  Eur J Nucl Med Mol Imaging Volume: 51 Page(s): 4073 - 4082
  11/01/2024 Authors: Mushtaq A; Lawal IO; Muzahir S; Friend SC; Bhave M; Meisel JL; Torres MA; Styblo TM; Graham CL; Kalinsky K
• Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
  Breast Cancer Res Treat Volume: 207 Page(s): 599 - 609
  10/01/2024 Authors: Bhave MA; Quintanilha JCF; Tukachinsky H; Li G; Scott T; Ross JS; Pasquina L; Huang RSP; McArthur H; Levy MA
• Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
  Breast Cancer Res Treat Volume: 207 Page(s): 611 - 614
  10/01/2024 Authors: Bhave MA; Quintanilha JCF; Tukachinsky H; Li G; Scott T; Ross JS; Pasquina L; Huang RSP; McArthur H; Levy MA
• Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
  J Clin Invest Volume: 134
  03/26/2024 Authors: Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y
• Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy.
  Clin Breast Cancer Volume: 23 Page(s): 832 - 834
  12/01/2023 Authors: Aldrich J; Canning M; Bhave M
• Neratinib+ fulvestrant+ trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
  Ann Oncol Volume: 34 Page(s): 885 - 898
  10/01/2023 Authors: Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES
• A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment.
  Clin Nucl Med Volume: 48 Page(s): e202 - e203
  04/01/2023 Authors: Adediran OA; Lawal IO; Muzahir S; Bhave MA; Friend S; Fielder B; Meisel J; Torres MA; Styblo TM; Graham C
• Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center.
  Clin Breast Cancer Volume: 23 Page(s): 38 - 44
  01/01/2023 Authors: Aldrich J; Ekpo P; Rupji M; Switchenko JM; Torres MA; Kalinsky K; Bhave MA
• A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.
  Clin Nucl Med Volume: 48 Page(s): e26 - e27
  01/01/2023 Authors: Lawal IO; Adediran OA; Muzahir S; Friend S; Bhave MA; Meisel J; Torres MA; Styblo TM; Graham C; Holbrook A
• Spatially variant immune infiltration scoring in human cancer tissues.
  NPJ Precis Oncol Volume: 6 Page(s): 60
  09/01/2022 Authors: Allam M; Hu T; Lee J; Aldrich J; Badve SS; Gkmen-Polar Y; Bhave M; Ramalingam SS; Schneider F; Coskun AF
• Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
  Transl Lung Cancer Res Volume: 9 Page(s): 1015 - 1028
  08/01/2020 Authors: Chae YK; Kim WB; Davis AA; Park LC; Anker JF; Simon NI; Rhee K; Song J; Cho A; Chang S
• Outcomes for black versus white women with stage IV breast cancer enrolled on investigator-initiated clinical trials at Emory.
  Volume: 38
  05/20/2020 Authors: Ekpo P; Torres MA; Rupji M; Switchenko JM; Subhedar P; Gogineni K; Bhave MA
• Breast cancer patient reported outcomes, depression, and objective measures of breast cosmesis.
  Volume: 38
  05/20/2020 Authors: McManus S; Lin JY; Bhave MA; Brown G; Green I; Yang X; Liu T; Miller AH; Torres MA
• Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
  Ann Surg Oncol Volume: 26 Page(s): 3152 - 3158
  10/01/2019 Authors: Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
• Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers.
  Volume: 37
  05/20/2019 Authors: Bhave MA; Fang F; Kidwell KM; Smith GL; Chugh R; Burness ML
• Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.
  Oncotarget Volume: 9 Page(s): 22137 - 22146
  04/24/2018 Authors: Costa RB; Costa RLB; Talamantes SM; Kaplan JB; Bhave MA; Rademaker A; Miller C; Carneiro BA; Mahalingam D; Chae YK
• Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
  Clin Breast Cancer Volume: 18 Page(s): 168 - 174.e2
  04/01/2018 Authors: Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
• Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.
  Cancer Treat Rev Volume: 63 Page(s): 116 - 121
  02/01/2018 Authors: Chae YK; Galvez C; Anker JF; Iams WT; Bhave M
• Extended Endocrine Therapy: Is 5Years Enough?
  Curr Oncol Rep Volume: 19 Page(s): 16
  03/01/2017 Authors: Bhave MA; Henry NL
• An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity.
  Curr Opin Oncol Volume: 26 Page(s): 590 - 599
  11/01/2014 Authors: Bhave M; Shah AN; Akhter N; Rosen ST
• Research essentials.
  Nurs Child Young People Volume: 26 Page(s): 12
  04/01/2014 Authors: Bray L; Chapman S
• Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events.
  Hepatology Volume: 56 Page(s): 1741 - 1750
  11/01/2012 Authors: Vanwagner LB; Bhave M; Te HS; Feinglass J; Alvarez L; Rinella ME
• Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options.
  Autoimmun Rev Volume: 10 Page(s): 311 - 316
  04/01/2011 Authors: Shetty S; Bhave M; Ghosh K
• Challenges of multiple mutations in individual patients with haemophilia.
  Eur J Haematol Volume: 86 Page(s): 185 - 190
  03/01/2011 Authors: Shetty S; Bhave M; Ghosh K